Metsera (NASDAQ:MTSR) Rating Lowered to Sell at Wall Street Zen

Metsera (NASDAQ:MTSR) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Tuesday.

Several other analysts have also recently commented on the stock. Guggenheim boosted their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, June 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Metsera in a research report on Wednesday, September 3rd. Leerink Partners initiated coverage on Metsera in a research report on Tuesday, September 9th. They issued an “outperform” rating and a $77.00 target price on the stock. Wells Fargo & Company started coverage on Metsera in a report on Friday, June 20th. They set an “overweight” rating and a $65.00 price objective on the stock. Finally, Bank of America upped their price target on shares of Metsera from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Metsera currently has a consensus rating of “Buy” and a consensus target price of $58.50.

Metsera Stock Performance

Shares of Metsera stock opened at $52.50 on Tuesday. The stock’s 50-day simple moving average is $36.09 and its 200-day simple moving average is $29.68. Metsera has a 52 week low of $12.30 and a 52 week high of $54.47.

Metsera (NASDAQ:MTSR) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MTSR. Alphabet Inc. purchased a new position in Metsera during the 1st quarter valued at about $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in Metsera during the first quarter valued at approximately $78,748,000. Wellington Management Group LLP purchased a new position in shares of Metsera in the 1st quarter valued at $65,382,000. Alpha Wave Global LP purchased a new position in shares of Metsera in the 1st quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Metsera in the 1st quarter valued at $42,395,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.